BioCryst Pharmaceuticals, Inc.
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930ā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.12
Price-2.05%
-$0.17
1Y
Price
Market Cap
$2.064b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+45.3%
EBITDA Margin+35.9%
Net Profit Margin+47.7%
Free Cash Flow Margin+45.3%
EBITDA Margin+35.9%
Net Profit Margin+47.7%
Free Cash Flow MarginRevenue
$940.613m
+7.5%
1y CAGR+45.9%
3y CAGR+40.0%
5y CAGREarnings
-$384.673m
-245.8%
1y CAGR+70.6%
3y CAGR+55.1%
5y CAGREPS
-$1.50
-224.0%
1y CAGR+73.7%
3y CAGR+58.1%
5y CAGRBook Value
-$454.289m
$557.851m
Assets$1.012b
Liabilities$409.856m
DebtDebt to Assets
73.5%
-1.3x
Debt to EBITDAFree Cash Flow
$357.108m
+9.1%
1y CAGR+256.9%
3y CAGR+202.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company